Prevenar 13 Vaccine
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Prevenar 13 Vaccine (PCV13) is a 13-valent pneumococcal polysaccharide conjugate vaccine. Its labelling describes it as protecting against 13 types of pneumococcal bacteria that can cause pneumonia, otitis media (middle-ear infection), and meningitis. It is described for routine immunisation of infants and children and for adults aged 18 years and over, and it is administered by a healthcare professional.
Product Information
The following description reflects information associated with the 13-valent pneumococcal polysaccharide conjugate vaccine and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for the prevention of pneumonia, meningitis, and middle-ear infection caused by 13 types of pneumococcal bacteria
- Described for routine immunisation of infants and children
- Described for adults aged 18 years and over
- Described as helping the body make antibodies against pneumococcal disease
Described Dosage & Administration
- Administered only by a doctor or nurse into the muscle — not self-administered
- All doses in the course should be completed for the vaccine to work as intended
- Infants are described as given three doses starting at 6 weeks of age
- A single dose is described as usually enough for adults or older children, unless the healthcare provider advises otherwise
Described Side Effects
Commonly described side effects include:
- Injection-site reactions (pain, swelling, redness)
- Irritability
- Sleepiness
These are described as not causing harm and usually short-lived. If they last a long time, or for any severe, persistent, or unexpected reaction, prompt medical attention is required.
Precautions
- The doctor should be consulted if the recipient currently has any illness before receiving the vaccine
- The doctor should be told about all other medicines being taken, as they are described as possibly altering the response to the vaccine
- Pregnant women and breastfeeding mothers should consult their doctor before receiving the vaccine
- Any previous allergic reaction to a vaccine or vaccine component should be disclosed beforehand
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it is a 13-valent pneumococcal conjugate vaccine used to help prevent pneumonia, meningitis, and middle-ear infection caused by 13 types of pneumococcal bacteria, for routine immunisation of infants and children and for adults aged 18 and over. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling states it is administered by a doctor or nurse into the muscle. Infants are described as given three doses starting at 6 weeks of age, while a single dose is described as usually enough for adults or older children unless the healthcare provider advises otherwise.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.